Skip to Content
Søk Menu

ASH2020: Early vs Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Related

New Treatment Relapsed/Refractory Mantle Cell Lymphoma - data from phase 1 study

/ Maria Lia Palomba
ASH20Lymfom Play the Video 12:30

DARA to Rd continues to demonstrate a superior PFS benefit

/ Shaji K. Kumar
ASH20Myelomatose Play the Video 7:23

Promising clinical response for CD19-CART-cell therapy in CLL

/ Ohad Benjamini
ASH20KLL Play the Video 9:13

The First-in-Class Anti-CD47 Antibody for AML

/ David A. Sallman
ASH20Leukemi Play the Video 6:57

Recurrent Crebbp Mutations in Follicular Lymphoma

/ Joe Schroers-Martin
ASH20Lymfom Play the Video 11:53

Promising results for treatment of AML

/ Tapan M. Kadia
LeukemiASH20AML Play the Video 7:42

Updated efficacy data of maintenance therapy with DARA Plus RVd

/ Jonathan Kaufman
ASH20Myelomatose Play the Video 10:23

Subcutaneous Daratumumab in Multiple Myeloma shows reduced the risk of progression or death by 37%

/ BestPractice Nordic
ASH20Myelomatose

Subcutaneous Daratumumab in Multiple Myeloma shows reduced the risk of progression or death by 37%

/ BestPractice Nordic
ASH20Myelomatose
Back to top